Sectors News Results

  • Novartis unit Sandoz agrees to pay $195 mln to resolve antitrust charges

    Novartis' generic drugs unit Sandoz has agreed to pay $195 million to reach a deferred prosecution agreement aimed at resolving antitrust charges, the Justice Department said on Monday. The company was charged with rigging bids and fixing prices of more than $500 million worth of generic drugs between 2013-2015, said the department, which has been probing the generic drug industry for three years.

  • Teva Pharm regains market trust amid restructuring

    * Q4 results just beat expectations. * Teva shares surge 9% after its results. * Company cut manufacturing sites, slashed jobs. * CEO says 2019 was a trough year for earnings. By Tova Cohen and Steven Scheer.

Search News

Filter Results

Publication Date
Topic
Provider

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.